Advertisement
Research ArticleDrug Discovery and Translational Medicine
Open Access

Mechanism of Action of Veverimer: A Novel, Orally Administered, Nonabsorbed, Counterion-Free, Hydrochloric Acid Binder under Development for the Treatment of Metabolic Acidosis in Chronic Kidney Disease

Gerrit Klaerner, Jun Shao, Kalpesh Biyani, Matthew Kade, Paul Kierstead, Randi Gbur, Scott Tabakman, Son Nguyen and Jerry Buysse
Journal of Pharmacology and Experimental Therapeutics December 2020, 375 (3) 439-450; DOI: https://doi.org/10.1124/jpet.120.000190
Submit a Response to This Article
Compose eLetter

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools
Research ArticleDrug Discovery and Translational Medicine

Mechanism of Action of Veverimer

Gerrit Klaerner, Jun Shao, Kalpesh Biyani, Matthew Kade, Paul Kierstead, Randi Gbur, Scott Tabakman, Son Nguyen and Jerry Buysse
Journal of Pharmacology and Experimental Therapeutics December 1, 2020, 375 (3) 439-450; DOI: https://doi.org/10.1124/jpet.120.000190
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section